News Focus
News Focus
Post# of 257269
Next 10
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

Re: DewDiligence post# 209073

Friday, 12/10/2021 9:07:16 AM

Friday, December 10, 2021 9:07:16 AM

Post# of 257269
HOLX touts proprietary diagnostic for deciding whether to administer extended (2.5-5yr) endocrine therapy in ER+ HER2- breast cancer:

https://www.businesswire.com/news/home/20211210005080/en

HOLX is the leading manufacturer of 3D mammogram devices.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today